Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Pasithea Therapeutics Corp.

KTTA · Nasdaq · CIK 0001841330 · Healthcare · Biotechnology

INSIDER SIGNAL

37.8 / 100

1 buyers · 1 purchase transaction lines · $53.0K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+5.5 / 25
Role+14.0 / 20
Recency+1.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Role scores low · most senior buyer: TenPercentOwner (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Coastlands Capital LPTenPercentOwner
●
● Purchase▼ Sale○ Other

—

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: Coastlands Capital LP · $53.0K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-06-17–2026-06-17

Roles in the peak window: TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

37.8 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 38.0
  2. 37.9
  3. 37.8
  4. 37.8
  5. 37.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
0Sales
2Other Form 4 lines
6SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-13.3%
3M
-4.5%
6M
-33.1%
12M
-42.9%

Volatility & liquidity

Volatility
131.6%
Beta
—
Avg daily value
USD 103,373

Valuation

Market cap
USD 15.6M
P/E
—

Fundamentals

Profit margin
—
ROE
-37.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-12 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
159,831
Previous report
270,085
Avg daily volume
151,144
Days to cover
1.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-17Coastlands Capital LPPurchase (P)Common Stock100,000USD 0.53USD 53,000SEC filing ↗
2025-11-28STEINMAN LAWRENCEPurchase (P)Common Stock133,333USD 0.75USD 100,000SEC filing ↗
2025-11-28Marques TiagoPurchase (P)Common Stock33,333USD 0.75USD 25,000SEC filing ↗
2025-11-28Dumesnil SimonPurchase (P)Common Stock33,333USD 0.75USD 25,000SEC filing ↗
2023-06-02STEINMAN LAWRENCEPurchase (P)Common Stock30,000USD 0.43USD 12,900SEC filing ↗
2022-10-17Concord IP2 Ltd.; Delaney David; Elderhill CorpPurchase (P)Common Stock1,000USD 1.11USD 1,110SEC filing ↗
2022-09-29Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock6,710USD 1.16USD 7,784SEC filing ↗
2022-09-28Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock57,647USD 1.19USD 68,600SEC filing ↗
2022-09-06Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock21,748USD 1.13USD 24,575SEC filing ↗
2022-09-02Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock11,507USD 1.14USD 13,118SEC filing ↗
2022-09-01Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock55,646USD 1.13USD 62,880SEC filing ↗
2022-08-30Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock17,828USD 1.15USD 20,502SEC filing ↗
2022-08-29Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock5,000USD 1.17USD 5,850SEC filing ↗
2022-08-19Geller Avi; Leonite Capital LLC; Leonite Fund I, LPPurchase (P)Common Stock54,644USD 1.30USD 71,037SEC filing ↗
2022-08-17Camac Capital, LLC; Camac Fund, LP; Camac Partners, LLC; Shahinian EricPurchase (P)Common Stock155,773USD 1.21USD 188,485SEC filing ↗

Form 4 evidence

6 transaction lines in the latest 365-day window; 43 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-17Coastlands Capital LPPurchase (P)Common Stock100,000USD 0.53USD 53,000SEC filing ↗
2025-11-28Schneiderman Daniel HAward / grant (A)Common Stock26,667USD 0.75USD 20,000SEC filing ↗
2025-11-28STEINMAN LAWRENCEPurchase (P)Common Stock133,333USD 0.75USD 100,000SEC filing ↗
Show recent Form 4 evidence (6 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-06-17Coastlands Capital LPPurchase (P)Common Stock100,000USD 0.53USD 53,000SEC filing ↗
2025-11-28Schneiderman Daniel HAward / grant (A)Common Stock26,667USD 0.75USD 20,000SEC filing ↗
2025-11-28STEINMAN LAWRENCEPurchase (P)Common Stock133,333USD 0.75USD 100,000SEC filing ↗
2025-11-28Marques TiagoPurchase (P)Common Stock33,333USD 0.75USD 25,000SEC filing ↗
2025-11-28Leahy EmerAward / grant (A)Common Stock33,333USD 0.75USD 25,000SEC filing ↗
2025-11-28Dumesnil SimonPurchase (P)Common Stock33,333USD 0.75USD 25,000SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerKTTA
CIK0001841330
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history43 transaction lines from 2021-12-20 to 2026-06-17
15 P purchase lines · 1 S sale lines · 27 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.